These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29677050)

  • 21. Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.
    de Vries LV; Dobrowolski LC; van den Bosch JJ; Riphagen IJ; Krediet CT; Bemelman FJ; Bakker SJ; Navis G
    Am J Kidney Dis; 2016 Jun; 67(6):936-44. PubMed ID: 26803690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggressive antihypertensive treatment and serum lipid lowering therapy are necessary to prevent deterioration of the renal function even in elderly type 2 diabetic patients with persistent albuminuria.
    Narita T; Kakei M; Ito S
    Gerontology; 2002; 48(5):302-8. PubMed ID: 12169796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum uric acid level is associated with metabolic syndrome and microalbuminuria in Korean patients with type 2 diabetes mellitus.
    Kim ES; Kwon HS; Ahn CW; Lim DJ; Shin JA; Lee SH; Cho JH; Yoon KH; Kang MI; Cha BY; Son HY
    J Diabetes Complications; 2011; 25(5):309-13. PubMed ID: 21130003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of chronic kidney disease in type 2 diabetes: A longitudinal study from the AMD Annals initiative.
    De Cosmo S; Viazzi F; Pacilli A; Giorda C; Ceriello A; Gentile S; Russo G; Rossi MC; Nicolucci A; Guida P; Pontremoli R;
    Medicine (Baltimore); 2016 Jul; 95(27):e4007. PubMed ID: 27399078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.
    Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A;
    Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
    Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
    J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.
    Nosadini R; Velussi M; Brocco E; Bruseghin M; Abaterusso C; Saller A; Dalla Vestra M; Carraro A; Bortoloso E; Sambataro M; Barzon I; Frigato F; Muollo B; Chiesura-Corona M; Pacini G; Baggio B; Piarulli F; Sfriso A; Fioretto P
    Diabetes; 2000 Mar; 49(3):476-84. PubMed ID: 10868971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.
    Apperloo EM; Pena MJ; de Zeeuw D; Denig P; Heerspink HJL
    Diabetes Obes Metab; 2018 Jun; 20(6):1377-1383. PubMed ID: 29345404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients.
    Tanaka N; Babazono T; Takagi M; Yoshida N; Toya K; Nyumura I; Hanai K; Uchigata Y
    Nephrology (Carlton); 2015 Aug; 20(8):531-8. PubMed ID: 25773273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT).
    Diabetes; 2001 Apr; 50(4):843-50. PubMed ID: 11289051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Type 2 diabetes mellitus and chronic kidney disease].
    Ponťuch P
    Vnitr Lek; 2017; 63(3):188-192. PubMed ID: 28379021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes.
    van den Born JC; Frenay AR; Bakker SJ; Pasch A; Hillebrands JL; Lambers Heerspink HJ; van Goor H
    Nitric Oxide; 2016 May; 55-56():18-24. PubMed ID: 26952289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for the development of microalbuminuria and interaction with renal function.
    Chatzikyrkou C; Menne J; Izzo J; Viberti G; Rabelink T; Ruilope LM; Rump C; Mertens PR; Haller H
    J Hypertens; 2017 Dec; 35(12):2501-2509. PubMed ID: 29035939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study.
    Muiesan ML; Ambrosioni E; Costa FV; Leonetti G; Pessina AC; Salvetti M; Trimarco B; Volpe M; Pontremoli R; Deferrari G; Rosei EA
    J Hypertens; 2012 Dec; 30(12):2378-86. PubMed ID: 23137952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.